Configure Section Container Component

hATTR therapies use different approaches to target TTR protein2

divider line
Liver Icon
Liver2,3
arrow icon
arrow icon
Transthyretin Tetramer Destabilizes
TTR tetramer dissociation
arrow icon
arrow icon
Tetramer Dissociates Into Monomers
Monomers misfold
arrow icon
arrow icon
Monomers Misfold And Aggregate Into Amyloid Fibrils
Amyloid fibril formation
arrow icon
arrow icon
Amyloid Deposits Throughout The Body
Deposition
arrow icon

A SILENCER TARGETS TTR mRNA2,4

TTR mRNA Degradation
TTR mRNA
DNA Silencerarrow icon
Silencer
arrow icon
mRNA Targeted Degradation
mRNA-targeted degradation
arrow icon
arrow icon
Reduced TTR Protein Levels
Reduced TTR protein levels
arrow icon

A STABILIZER BINDS TO TTR TETRAMERS2,4,5

Unstable Tetramer
Unstable
tetramer
TTR Stabilizerarrow icon
Stabilizer
arrow icon
Prevents Tetramer Dissociation
Prevents tetramer dissociation
arrow icon
arrow icon
Reduced TTR Dissociation and Misfolding
Reduced TTR dissociation and misfolding
Configure Accordion Item: -
accordionUniqueIDDescription - manage-attr-mobile

Configure Accordion Item: -

A SILENCER
TARGETS TTR mRNA2,4

TTR mRNA
TTR mRNA
Silencer
Silencer
mRNA-targeted degradation
mRNA-targeted degradation
Reduced TTR protein levels
Reduced TTR protein levels
Configure Accordion Item: -
accordionUniqueIDDescription - manage-attr-mobile

Configure Accordion Item: -

A STABILIZER BINDS TO TTR TETRAMERS2,4,5

Unstable tetramer
Unstable tetramer
Silencer
Stabilizer
Prevents tetramer dissociation
Prevents tetramer dissociation
Reduced TTR dissociation and misfolding
Reduced TTR dissociation
and misfolding
Monomers misfold
Monomers misfold
Amyloid fibril formation
Amyloid fibril formation
Deposition
Deposition
Configure Section Container Component

mRNA, messenger ribonucleic acid; TTR, transthyretin.

Discover a treatment option for your patients
with polyneuropathy of hATTR

References: 1. Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109-2122. 2. Tschöpe C, Elsanhoury A. Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges. J Clin Med. 2022;11(8):2148. 3. Ioannou A, Fontana M, Gillmore JD. RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs. 2023;37(2):127-142. 4. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568. 5. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086-1097.

Modal Window Component Section Begins
Modal Window Component Section Ends
Configure Footer Reference Component
Reference
Back to top